Pneumonia Therapeutics Market Expected To Secure Notable Revenue Share By 2026

-

Pneumonia Therapeutics Market Size is expected to exceed USD 2.8 Bn by 2026. Increasing government initiatives for the treatment of pneumonia will significantly accelerate the overall business progression. Increasing incidence of pneumococcal disease worldwide will drive the market growth from 2020 to 2026. Pneumococcal disease is caused by Streptococcus pneumonia and can infect the lungs causing blood infection, middle ear infection and bacterial meningitis among others.
The  U.S. pneumonia therapeutics market will witness around 6.3% CAGR and is projected to witness substantial growth during the analysis period. The country growth can be attributed due to increasing geriatric population base, leading to surging demand for pneumonia therapeutic drugs. Additionally, increasing number of hospital admissions for the treatment of pneumonia will enhance the country progression.

Request sample copy of this Report @  https://www.gminsights.com/request-sample/detail/2029

Based on drug class, the market is segmented into antiviral drugs, antibacterial drugs and antifungal drugs. The antibacterial drugs segment accounted for over 60% revenue share in 2019 and are further classified into quinolones and macrolides among others. Antibacterial drugs are widely used to treat community-acquired pneumonia. Furthermore, macrolides antibiotics such as clarithromycin, azithromycin and others are useful for children to protect them from pneumonia, thereby enhancing the segmental growth. 

Based on the age group, the industry is segmented into pediatric, adult and geriatric. The pediatric segment will exhibit 7.5% CAGR during the analysis period. Children especially with weak immune system are at higher risk of acquiring pneumonia. As child’s immune system is often weak and underdeveloped, the chances of developing pneumonia are much higher. Also, children having cystic fibrosis or asthma problems, and lungs associated disorders further creates higher need for antiviral and antibacterial drugs. Thus, increased risk of pneumonia in pediatric patients augments the segmental growth. 

The infection type segment covers hospital acquired pneumonia (HAP), community acquired pneumonia (CAP) and ventilator associated pneumonia (VAP). The community acquired pneumonia segment accounted for around USD 1.3 Bn in 2019. CAP is one of the most common infectious diseases occurring worldwide. CAP refers to the pneumonia that is acquired by individuals outside the hospital. CAP is one of the most common cause of lung infections in people of 5 to 35 years of age. Increasing prevalence of community acquired pneumonia will enhance the segmental growth.

Browse key industry insights spread across 180 pages with 176 market data tables & 14 figures & charts from the report, “Pneumonia Therapeutics Market Size By Drug Class (Antibacterial Drugs {Quinolones, Macrolide}, Antiviral Drugs, Antifungal Drugs), By Age Group (Pediatric, Adult, Geriatric), By Infection Type (Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP), Ventilator-associated Pneumonia (VAP), By Distribution Channel, (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/pneumonia-therapeutics-market


Some major findings of the pneumonia therapeutics market report include:

  • Increasing incidence of ventilator-associated and community-acquired bacterial pneumonia will boost the pneumonia therapeutics business growth
  • Rising number of clinical trials for the development of new and more effective drug molecules will enhance the pneumonia therapeutics market growth
  • Rising awareness among patients regarding pneumonia treatment aids the industry growth
  • Surging incidence of pneumococcal disease among young population base across the globe will ultimately foster the market growth


Some of the prominent business players operating in pneumonia therapeutics industry include Abbott Laboratories, Allergan, Bayer, Cipla, Lupin Pharmaceuticals, Mylan, Novartis, Sanofi, Pfizer, Merck, AstraZeneca and GlaxoSmithKline. These market players are focusing on developing new products that helps the firm to expand its overall geographical presence.

Request for customization:  @ https://www.gminsights.com/roc/2029

About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com     
Web: https://www.gminsights.com/          


Comments

Post a Comment

Popular posts from this blog

Cancer diagnostics market statistics and research analysis released in latest report

-
  A research study conducted by Global Market Insights, Inc., suggests that Cancer Diagnostics Market is likely to exceed the $170 billion mark by 2025, in terms of revenue. Growing awareness regarding early disease diagnosis coupled with increasing number of diagnostic and research laboratories will drive cancer diagnostics market demand over the forthcoming time period. Evolving healthcare infrastructure of developing countries, rising awareness about cancer, and increasing healthcare spending will further influence the market growth positively. With growing prevalence of cancer cases across the globe, key industry players are increasingly focusing on consolidating their position in the market through several tried-and-tested methods. Citing an instance, on 29 th June 2020, BioCare Medical, a renowned provider of automated, innovative, immunohistochemistry (IHC) instrumentation and reagents, reportedly announced a collaborative partnership with Bethyl Laboratories for developing ta
Read more

Laparoscopic Instruments market research report by 2020 to 2026

-
  A research study conducted by Global Market Insights, Inc., suggests that Laparoscopic Instruments market is likely to exceed the $ 20 billion mark by 2026, in terms of revenue. owing to the rising incidence of colorectal cancer. According to reliable estimates, colorectal cancer is the third most common cancer diagnosis with death due to cancer seen in both men and women across industrialized nations. Given the increasing prevalence of cancer cases, the demand for laparoscopic procedures will also increase tremendously, thereby boosting the market growth.   With ongoing technological advancements and new innovations, the laparoscopic instruments market is slated to further witness tremendous growth over the coming years. While robotic surgery is not new in the medical field, new advancements in the field of robotic hardware and software will augment the next gen of tools and instruments that would enhance the skills of physicians and patient outcomes Request for a sample copy o
Read more

Botulinum Toxin industry analysis research and trends report for 2020- 2026

-
A research study conducted by Global Market Insights, Inc., suggests that Botulinum Toxin market is likely to exceed the $8.9 billion mark by 2026, in terms of revenue. Botulinum toxin market trends are likely to be driven by the escalating demand for cosmetic treatment to reduce laxity, facial wrinkles and other non-invasive procedures for beauty enhancement. The pursuit of beauty and youth has undergone a revival of interest as evinced by rise in visits of individuals to cosmetology clinics. Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3408 The recent approval of the potent botulinum toxin Dysport, which is the first and only FDA approved toxin for the treatment of lower and upper limb spasticity in both pediatrics and adults, will offer several opportunities for the industry players over the coming years. A report suggests that global botulinum toxin market size will cross the USD 8.9 billion mark by 2026. Botulinum toxin A is
Read more